<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-0MIL863G/05bda8d1-cb00-4711-9849-388f498d88cc/PDF"><dcterms:extent>2151 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-0MIL863G/b01f1b94-b25d-4564-9028-9c0e85791a41/TEXT"><dcterms:extent>0 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="1998-2025"><edm:begin xml:lang="en">1998</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-0MIL863G"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-KC6O72BG" /><dcterms:issued>2024</dcterms:issued><dc:creator>Albreht, Alen</dc:creator><dc:creator>Sharma, Kuldeepak</dc:creator><dc:creator>Zajc, Irena</dc:creator><dc:creator>Žiberna, Lovro</dc:creator><dc:format xml:lang="sl">številka:4</dc:format><dc:format xml:lang="sl">letnik:71</dc:format><dc:format xml:lang="sl">str. 627-645</dc:format><dc:identifier>DOI:10.17344/acsi.2024.8964</dc:identifier><dc:identifier>ISSN:1580-3155</dc:identifier><dc:identifier>COBISSID_HOST:220977155</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-0MIL863G</dc:identifier><dc:language>en</dc:language><dc:publisher xml:lang="sl">Slovensko kemijsko društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Acta chimica slovenica</dcterms:isPartOf><dc:subject xml:lang="sl">antioksidant</dc:subject><dc:subject xml:lang="en">antioxidant</dc:subject><dc:subject xml:lang="en">bilirubin</dc:subject><dc:subject xml:lang="en">biliverdin</dc:subject><dc:subject xml:lang="en">biliverdin reductase</dc:subject><dc:subject xml:lang="sl">biliverdin reduktaza</dc:subject><dc:subject xml:lang="sl">človeški endotelij</dc:subject><dc:subject xml:lang="sl">Endotelij</dc:subject><dc:subject xml:lang="en">human endothelium</dc:subject><dc:subject xml:lang="sl">Kemija</dc:subject><dc:subject xml:lang="sl">Oksidativni stres</dc:subject><dc:subject xml:lang="en">oxidative stress</dc:subject><dc:subject xml:lang="sl">Učitelji</dc:subject><dcterms:temporal rdf:resource="1998-2025" /><dc:title xml:lang="sl">Inhibition of biliverdin reductase diminished the protective activity of bilirubin and biliverdin against oxidative stress-induced injury in human vascular endothelium|</dc:title><dc:description xml:lang="sl">Endothelial dysfunction, a key factor in cardiovascular diseases, is further aggravated by oxidative stress. Biliverdin (BV) and bilirubin (BR) are potent antioxidants that protect endothelial cells, with biliverdin reductase (BVR) converting BV to BR to maintain redox balance. This study explored BVR's role in mediating these protective effects under normoxic and hypoxia-reoxygenation conditions. Pharmacological inhibition of BVR reduced the protective effects of BV and BR, as evidenced by decreased cell viability, cellular antioxidant activity, and intracellular bilirubin levels. Activation of ERK1/2 reduced BVR's protective function, while its inhibition enhanced it. Additionally, disruption of the BVR-ERK interaction further modulated these effects, highlighting the BVR-ERK1/2 interaction sites as potential therapeutic targets for oxidative stress-induced endothelial dysfunction</dc:description><dc:description xml:lang="sl">Endotelijska disfunkcija je pomemben dejavnik tveganja za razvoj srčno-žilnih bolezni, njeno stanje pa dodatno poslabša oksidativni stres. Biliverdin (BV) in bilirubin (BR) sta močna antioksidanta, ki ščitita endotelijske celice, pri čemer encim biliverdin reduktaza (BVR) pretvarja BV v BR za vzdrževanje redoks ravnovesja. Naša raziskava je preučevala vlogo BVR pri posredovanju teh zaščitnih učinkov v normoksičnih pogojih in pogojih hipoksije-reoksigenacije. Farmakološka inhibicija BVR je zmanjšala zaščitne učinke BV in BR, kar se kaže v zmanjšani viabilnosti celic, znotrajcelični antioksidativni sposobnosti in nižjih ravneh znotrajceličnega bilirubina. Aktivacija ERK1/2 je zmanjšala zaščitno funkcijo BVR, medtem ko jo je njena inhibicija povečala. Poleg tega je zaviranje interakcije med BVR in ERK dodatno vplivalo na delovanje BV in BR, kar kaže, da bi lahko vezavna mesta interakcije BVR-ERK1/2 predstavljala potencialne terapevtske tarče za zdravljenje endotelijske disfunkcije, povzročene z oksidativnim stresom</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-0MIL863G"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-0MIL863G" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-0MIL863G/05bda8d1-cb00-4711-9849-388f498d88cc/PDF" /><edm:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko kemijsko društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-0MIL863G/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-0MIL863G" /></ore:Aggregation></rdf:RDF>